These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35350994)

  • 1. Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer.
    van de Ven M; IJzerman M; Retèl V; van Harten W; Koffijberg H
    BMC Med Res Methodol; 2022 Mar; 22(1):83. PubMed ID: 35350994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer.
    Simons MJHG; Retèl VP; Ramaekers BLT; Butter R; Mankor JM; Paats MS; Aerts JGJV; Mfumbilwa ZA; Roepman P; Coupé VMH; Uyl-de Groot CA; van Harten WH; Joore MA
    Pharmacoeconomics; 2021 Dec; 39(12):1429-1442. PubMed ID: 34405371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer.
    Simons MJHG; Uyl-de Groot CA; Retèl VP; Mankor JM; Ramaekers BLT; Joore MA; van Harten WH
    Value Health; 2023 Jan; 26(1):71-80. PubMed ID: 35973926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE).
    Samsom KG; Bosch LJW; Schipper LJ; Roepman P; de Bruijn E; Hoes LR; Riethorst I; Schoenmaker L; van der Kolk LE; Retèl VP; Frederix GWJ; Buffart TE; van der Hoeven JJM; Voest EE; Cuppen E; Monkhorst K; Meijer GA
    BMC Med Genomics; 2020 Nov; 13(1):169. PubMed ID: 33167975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing.
    Pasmans CTB; Tops BBJ; Steeghs EMP; Coupé VMH; Grünberg K; de Jong EK; Schuuring EMD; Willems SM; Ligtenberg MJL; Retèl VP; van Snellenberg H; de Bruijn E; Cuppen E; Frederix GWJ
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):413-414. PubMed ID: 33852815
    [No Abstract]   [Full Text] [Related]  

  • 6. Whole genome sequencing in oncology: using scenario drafting to explore future developments.
    van de Ven M; Simons MJHG; Koffijberg H; Joore MA; IJzerman MJ; Retèl VP; van Harten WH
    BMC Cancer; 2021 May; 21(1):488. PubMed ID: 33933021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Operational models and criteria for incorporating microbial whole genome sequencing in hospital microbiology - A systematic literature review.
    Mintzer V; Moran-Gilad J; Simon-Tuval T
    Clin Microbiol Infect; 2019 Sep; 25(9):1086-1095. PubMed ID: 31039443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice.
    Samsom KG; Bosch LJW; Schipper LJ; Schout D; Roepman P; Boelens MC; Lalezari F; Klompenhouwer EG; de Langen AJ; Buffart TE; van Linder BMH; van Deventer K; van den Burg K; Unmehopa U; Rosenberg EH; Koster R; Hogervorst FBL; van den Berg JG; Riethorst I; Schoenmaker L; van Beek D; de Bruijn E; van der Hoeven JJM; van Snellenberg H; van der Kolk LE; Cuppen E; Voest EE; Meijer GA; Monkhorst K
    Nat Protoc; 2024 Mar; 19(3):700-726. PubMed ID: 38092944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early technology assessment of using whole genome sequencing in personalized oncology.
    Simons M; Van De Ven M; Coupé V; Joore M; IJzerman M; Koffijberg E; Frederix G; Uyl-De Groot C; Cuppen E; Van Harten W; Retèl V
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):343-351. PubMed ID: 33910430
    [No Abstract]   [Full Text] [Related]  

  • 10. Developing an efficient scheduling template of a chemotherapy treatment unit: A case study.
    Ahmed Z; Elmekkawy T; Bates S
    Australas Med J; 2011; 4(10):575-88. PubMed ID: 23386870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micro-costing of genetic diagnostics in acute leukemia in Sweden: from standard-of-care to whole-genome sequencing.
    Thangavelu T; Wirta V; Orsmark-Pietras C; Cavelier L; Fioretos T; Barbany G; Olsson-Arvidsson L; Pandzic T; Staffas A; Rosenquist R; Levin LÅ
    J Med Econ; 2024; 27(1):1053-1060. PubMed ID: 39101813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Views from the clinic: Healthcare provider perspectives on whole genome sequencing in paediatrics.
    Szego MJ; Meyn MS; Shuman C; Zlotnik Shaul R; Anderson JA; Bowdin S; Monfared N; Hayeems RZ
    Eur J Med Genet; 2019 May; 62(5):350-356. PubMed ID: 30503855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Whole-genome sequencing in German clinical practice : Economic impacts of its use in selected areas of application].
    Plöthner M; Frank M; Graf von der Schulenburg JM
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Feb; 60(2):143-150. PubMed ID: 27999872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical issues in implementing whole-genome-sequencing in routine diagnostic microbiology.
    Rossen JWA; Friedrich AW; Moran-Gilad J;
    Clin Microbiol Infect; 2018 Apr; 24(4):355-360. PubMed ID: 29117578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of whole genome sequencing in neurodevelopmental disorders.
    Runheim H; Pettersson M; Hammarsjö A; Nordgren A; Henriksson M; Lindstrand A; Levin LÅ; Soller MJ
    Sci Rep; 2023 Apr; 13(1):6904. PubMed ID: 37106068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma.
    Raman L; Van der Linden M; Van der Eecken K; Vermaelen K; Demedts I; Surmont V; Himpe U; Dedeurwaerdere F; Ferdinande L; Lievens Y; Claes K; Menten B; Van Dorpe J
    Genome Med; 2020 Apr; 12(1):35. PubMed ID: 32317009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.
    Schipper LJ; Samsom KG; Snaebjornsson P; Battaglia T; Bosch LJW; Lalezari F; Priestley P; Shale C; van den Broek AJ; Jacobs N; Roepman P; van der Hoeven JJM; Steeghs N; Vollebergh MA; Marchetti S; Cuppen E; Meijer GA; Voest EE; Monkhorst K
    ESMO Open; 2022 Dec; 7(6):100611. PubMed ID: 36463731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practice.
    Samsom KG; Schipper LJ; Roepman P; Bosch LJ; Lalezari F; Klompenhouwer EG; de Langen AJ; Buffart TE; Riethorst I; Schoenmaker L; Schout D; van der Noort V; van den Berg JG; de Bruijn E; van der Hoeven JJ; van Snellenberg H; van der Kolk LE; Cuppen E; Voest EE; Meijer GA; Monkhorst K
    J Pathol; 2022 Oct; 258(2):179-188. PubMed ID: 35792649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using molecular testing and whole-genome sequencing for tuberculosis diagnosis in a low-burden setting: a cost-effectiveness analysis using transmission-dynamic modelling.
    Mugwagwa T; Abubakar I; White PJ
    Thorax; 2021 Mar; 76(3):281-291. PubMed ID: 33542086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scenario analysis and multi-criteria decision analysis to explore alternative reimbursement pathways for whole genome sequencing for blood cancer patients.
    Vu M; Degeling K; Westerman D; IJzerman MJ
    J Cancer Policy; 2024 Sep; 41():100501. PubMed ID: 39142605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.